Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Amphastar Pharmaceuticals Inc Market Cap
Based on ratings from 6 stock analysts, the Amphastar Pharmaceuticals Inc stock price is expected to increase by 33.36% in 12 months. This is calculated by using the average 12-month stock price forecast for Amphastar Pharmaceuticals Inc. The lowest target is $55 and the highest is $66. Please note analyst price targets are not guaranteed and could be missed completely.
Amphastar Pharmaceuticals Inc has a total of 6 Wall St Analyst ratings. There are 4 buy ratings, 2 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Amphastar Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of AMPH.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joe Quatrochi Wells Fargo | Overweight | $55 | Initiates | Nov 22, 2024 |
| Serge Belanger Needham | Hold | Reiterates | Aug 8, 2024 | |
| David Amsellem Piper Sandler | Overweight | $66 | Maintains | Aug 8, 2024 |
| David Amsellem Piper Sandler | Overweight | $71 | Reiterates | Jun 27, 2024 |
| Serge Belanger Needham | Hold | Reiterates | May 22, 2024 | |
| Serge Belanger Needham | Hold | Reiterates | May 9, 2024 | |
| Serge Belanger Needham | Hold | Reiterates | Apr 10, 2024 | |
| Ekaterina Knyazkova JP Morgan | Overweight | $60 | Initiates | Mar 5, 2024 |
| Jason Gerberry B of A Securities | Neutral | $63 | Initiates | Nov 17, 2023 |
| Glen Santangelo Jefferies | Buy | $70 | Reinstates | Jul 25, 2023 |
| Jacob Hughes Wells Fargo | Equal-Weight | $44 | Maintains | May 17, 2023 |
| David Amsellem Piper Sandler | Overweight | $40 | Maintains | Oct 25, 2022 |
| Glen Santangelo Jefferies | Buy | $36 | Assumes | Oct 21, 2022 |
| Tim Chiang Capital One | Overweight | $44 | Initiates | Jul 29, 2022 |
| Jacob Hughes Wells Fargo | Equal-Weight | $32 | Maintains | Mar 15, 2022 |
| David Amsellem Piper Sandler | Overweight | $35 | Maintains | Mar 11, 2022 |
| David Amsellem Piper Sandler | Overweight | $28 | Upgrade | Jan 7, 2022 |
Wells Fargo | Equal-Weight | $20 | Maintains | Mar 17, 2021 |
Wells Fargo | Equal-Weight | Downgrade | Jan 8, 2021 | |
Northland Capital Markets | Outperform | Upgrade | Oct 5, 2020 |
When did it IPO
2014
Staff Count
1,761
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - Specialty & Generic
CEO
Dr. Yongfeng Zhang Ph.D.
Market Cap
$2.11B
In 2023, AMPH generated $644.4M in revenue, which was a increase of 29.14% from the previous year. This can be seen as a signal that AMPH's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) executives will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 4, 2024, at 11:30 am EST. Access via their website.
Why It Matters - Amphastar's participation in a major healthcare conference could signal upcoming strategic insights or developments, impacting investor sentiment and stock performance.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Amphastar Pharmaceuticals' CFO and EVP will participate in a fireside chat at the Jefferies London Healthcare Conference on November 20, 2024. Access details available on their website.
Why It Matters - Participation in the Jefferies Healthcare Conference highlights Amphastar's commitment to investor engagement and may influence stock performance through increased visibility and potential insights into future strategies.
Wed, 06 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Amphastar Pharmaceuticals Inc. (AMPH) held its Q3 2024 earnings call, providing insights into financial performance and business developments for investors.
Why It Matters - Amphastar Pharmaceuticals' Q3 2024 earnings call reveals financial performance and strategic direction, impacting stock valuation, investor sentiment, and potential future growth.
Wed, 06 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Amphastar Pharmaceuticals reported Q3 2024 net revenues of $191.2 million and a GAAP net income of $40.4 million ($0.78 per share). Adjusted net income was $49.6 million ($0.96 per share).
Why It Matters - Amphastar's strong Q3 revenue and profit growth, driven by key products like BAQSIMI® and Primatene MIST®, signals robust financial health and potential for continued investor returns.
Wed, 06 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Amphastar's Q3 2024 revenue and EPS should be evaluated against Wall Street estimates and year-ago figures for a comprehensive performance assessment.
Why It Matters - Comparing Amphastar's revenue and EPS with Wall Street estimates and previous year figures provides insights into its growth trajectory and market positioning, influencing investment decisions.
Wed, 06 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Amphastar Pharmaceuticals (AMPH) reported Q3 earnings of $0.96 per share, below the Zacks estimate of $1.01 and down from $1.15 per share year-over-year.
Why It Matters - Amphastar's earnings miss signals potential operational issues or declining demand, which could lead to negative sentiment and impact stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
